Accuracy of Kinovea-based kinematic gait analysis compared to a three-dimensional motion analysis system in healthy dogs.

OBJECTIVE: The goal of this study was to compare the accuracy of kinematic measurements obtained using the 2-D video-based kinematic motion analysis (KMA) software Kinovea (version 0.9.5; http://www.kinovea.org) with 3-D KMA in healthy dogs. METHODS: In this prospective study, 3-D marker-based KMA (VICON-Nexus, version 2.12.1, and Procalc, version 1.6; VICON Motion Systems Ltd) was performed on healthy dogs (body weight ≥ 20 kg; height at withers > 50 cm) walking on a treadmill (study period: November 2022). Simultaneously, dogs were video recorded by 1 smartphone (iPhone SE; Apple Inc) at a 1.50-m distance perpendicular to the shoulder (60 frames per second; 1,920 X 1,080 pixels) for KMA using Kinovea. Joint angle and joint angle velocity of the shoulder, elbow, carpus, hip, stifle, and tarsus were calculated for 6 synchronized gait cycles. Each gait cycle was divided into 10 increments. The difference between 3-D KMA and Kinovea was assessed for each parameter using robust linear mixed-effects models. RESULTS: 34 dogs were included. The estimated joint angle difference between 3-D KMA and Kinovea was less than 2° for all shoulder and elbow gait cycle increments. For the carpus, hip, stifle, and tarsus, the difference was less than 2° in 9, 5, 4, and 4 out of 10 gait cycle increments, respectively. CONCLUSIONS: Kinovea provides accurate kinematic data for the shoulder and elbow of healthy dogs. Carpal, hip, stifle, and tarsal kinematics were less accurate. CLINICAL RELEVANCE: The use of Kinovea for clinical and research purposes remains limited. Future Kinovea-based studies are needed to investigate the accuracy of carpal, hip, stifle, and tarsal kinematics.

Endothelin-1 and adrenomedullin plasma levels after exposure to fludrocortisone, dexamethasone, and spironolactone.

We asked whether plasma concentrations of endothelin-1 (ET-1) or adrenomedullin (ADM) are altered by different activity states of the renin-angiotensin-aldosterone system (RAAS). Levels of ET-1 and ADM were studied in patients with primary aldosteronism (n = 15), essential hypertension (n = 15), and adrenal insufficiency (n = 7). Effects of fludrocortisone, dexamethasone, or spironolactone treatment on ET-1 and ADM levels were also analyzed. Plasma ET-1 and ADM concentrations did not differ significantly between the patient groups. After fludrocortisone, dexamethasone, or spironolactone treatment, both ET-1 and ADM did not change significantly. The data support the hypothesis that the RAAS is not directly linked with the ET-1/ADM system.